Omalizumab与过敏原免疫治疗呼吸道和食物过敏。

Q3 Medicine

Indian Journal of Tuberculosis Pub Date : 2025-01-01 DOI:10.1016/j.ijtb.2024.06.011

P.C. Kathuria , Manisha Rai

{"title":"Omalizumab与过敏原免疫治疗呼吸道和食物过敏。","authors":"P.C. Kathuria , Manisha Rai","doi":"10.1016/j.ijtb.2024.06.011","DOIUrl":null,"url":null,"abstract":"<div><div><span>Allergen Immunotherapy<span> (AIT) is the only disease modifying treatment option for patient with IgE mediated allergic disorder. Conventional subcutaneous immunotherapy<span> is associated with adverse events during build-up and maintenance phase but cluster allergen immunotherapy with monoclonal anti-IgE antibody (omalizumab) has complementary and synergistic effect. </span></span></span><em>Omalizumab plus AIT</em><span> can significantly enhance the efficacy, safety, and steroid-sparing effect of AIT by increasing target maintenance dose (TMD) and sustained unresponsiveness (SU) to allergen while decreasing the adverse events and severe systemic reactions. This review aims to highlight that combination of </span><span><span>omalizumab</span><em> plus AIT</em></span> is superior than AIT alone.</div></div>","PeriodicalId":39346,"journal":{"name":"Indian Journal of Tuberculosis","volume":"72 1","pages":"Pages 98-102"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Omalizumab with allergen immunotherapy in respiratory & food allergy\",\"authors\":\"P.C. Kathuria , Manisha Rai\",\"doi\":\"10.1016/j.ijtb.2024.06.011\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div><span>Allergen Immunotherapy<span> (AIT) is the only disease modifying treatment option for patient with IgE mediated allergic disorder. Conventional subcutaneous immunotherapy<span> is associated with adverse events during build-up and maintenance phase but cluster allergen immunotherapy with monoclonal anti-IgE antibody (omalizumab) has complementary and synergistic effect. </span></span></span><em>Omalizumab plus AIT</em><span> can significantly enhance the efficacy, safety, and steroid-sparing effect of AIT by increasing target maintenance dose (TMD) and sustained unresponsiveness (SU) to allergen while decreasing the adverse events and severe systemic reactions. This review aims to highlight that combination of </span><span><span>omalizumab</span><em> plus AIT</em></span> is superior than AIT alone.</div></div>\",\"PeriodicalId\":39346,\"journal\":{\"name\":\"Indian Journal of Tuberculosis\",\"volume\":\"72 1\",\"pages\":\"Pages 98-102\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Indian Journal of Tuberculosis\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S001957072400115X\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indian Journal of Tuberculosis","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S001957072400115X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

过敏原免疫疗法（AIT）是IgE介导的过敏性疾病患者唯一的疾病修饰治疗选择。传统的皮下免疫治疗与建立和维持阶段的不良事件相关，但单克隆抗ige抗体（omalizumab）的簇变应原免疫治疗具有互补和协同作用。Omalizumab联合AIT可通过增加靶维持剂量（TMD）和对过敏原的持续无反应性（SU），显著提高AIT的疗效、安全性和类固醇节约效果，同时减少不良事件和严重全身反应。本综述旨在强调omalizumab联合AIT优于单独AIT。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Omalizumab with allergen immunotherapy in respiratory & food allergy

Allergen Immunotherapy (AIT) is the only disease modifying treatment option for patient with IgE mediated allergic disorder. Conventional subcutaneous immunotherapy is associated with adverse events during build-up and maintenance phase but cluster allergen immunotherapy with monoclonal anti-IgE antibody (omalizumab) has complementary and synergistic effect. Omalizumab plus AIT can significantly enhance the efficacy, safety, and steroid-sparing effect of AIT by increasing target maintenance dose (TMD) and sustained unresponsiveness (SU) to allergen while decreasing the adverse events and severe systemic reactions. This review aims to highlight that combination of omalizumab plus AIT is superior than AIT alone.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Indian Journal of Tuberculosis Medicine-Infectious Diseases

CiteScore

2.80

自引率

0.00%

发文量

103

期刊介绍： Indian Journal of Tuberculosis (IJTB) is an international peer-reviewed journal devoted to the specialty of tuberculosis and lung diseases and is published quarterly. IJTB publishes research on clinical, epidemiological, public health and social aspects of tuberculosis. The journal accepts original research articles, viewpoints, review articles, success stories, interesting case series and case reports on patients suffering from pulmonary, extra-pulmonary tuberculosis as well as other respiratory diseases, Radiology Forum, Short Communications, Book Reviews, abstracts, letters to the editor, editorials on topics of current interest etc. The articles published in IJTB are a key source of information on research in tuberculosis. The journal is indexed in Medline